Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenibPhilippe Saïag, Caroline Dutriaux, Charlée Nardin et al.|European Journal of Cancer|2021Cited by 13
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastasesCaroline Dutriaux, Philippe Saïag, Caroline Robert et al.|European Journal of Cancer|2022Cited by 13
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Charlée Nardin, Stéphane Dalle et al.|Journal of the American Academy of Dermatology|2021Cited by 9
Long-term immune-related adverse events under PD-1 inhibitors: a multicenter prospective cohort study (MELBASE).Charlée Nardin, F. Aubin, Stéphane Dalle et al.|Journal of Clinical Oncology|2020Cited by 3
Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatmentS. Tzoumpa, E. Maubec, B. Villette et al.|Immunotherapy|2024Cited by 2